Lipid Or Oil Patents (Class 424/283.1)
-
Publication number: 20120093875Abstract: Aminocyclitol compounds and uses thereof as pharmaceutical compositions for the treatment of diseases associated with alterations in iNKT cells, more specifically autoimmune diseases, cancer, infections caused by pathogenic microorganisms or inflammatory diseases. Furthermore, the invention relates to the process for obtaining said compounds.Type: ApplicationFiled: September 20, 2011Publication date: April 19, 2012Inventors: Amadeo Llebaria Soldevilla, Carmen Bedia Girbés, Youssef Harrak Serifi, Angel Raul Castaño Garcia, Carolina Mercedes Barra Quaglia, Antonio Delgado Cirilo
-
Patent number: 8158133Abstract: A pharmaceutical composition including at least a mixture of at least one oil, at least one surfactant and an aqueous phase, itself including at least one active substance, the pharmaceutical composition not being in the form of an emulsion, but in the form of an oily isotrope.Type: GrantFiled: December 1, 2005Date of Patent: April 17, 2012Assignee: VetoquinolInventors: Marinette Moreau, Nicolas Osty
-
Publication number: 20120087976Abstract: The present invention relates to an aqueous adjuvant composition comprising a TLR-4 agonist and a saponin in a liposomal formulation and a non-ionic isotonicity agent having low salt concentrations.Type: ApplicationFiled: June 8, 2010Publication date: April 12, 2012Inventors: Veronique Henderickx, Dominique Ingrid Lemoine
-
Publication number: 20120064151Abstract: The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the avian species. The method is particularly effective for protecting a member of the avian species from infectious disease and treating animals inflicted with infectious disease.Type: ApplicationFiled: May 7, 2010Publication date: March 15, 2012Applicant: Bayer Animal Health GmbHInventor: Albert Abraham
-
Publication number: 20120064127Abstract: It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a) a lipid fraction comprising at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdenum, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.Type: ApplicationFiled: November 11, 2011Publication date: March 15, 2012Applicant: N.V.NUTRICIAInventor: Robert J.J. Hageman
-
Publication number: 20120058149Abstract: The invention relates to compositions including a substance useful as an adjuvant for potentiating an immune response, and methods of using the composition in individuals with infections of tissue within or adjacent to a transformation zone, such as the transformation zone of the cervix or anal canal.Type: ApplicationFiled: March 5, 2010Publication date: March 8, 2012Inventor: Jenny Colleen McCloskey
-
Publication number: 20120045389Abstract: The present invention provides a biosafe and useful vector to transfer genetic material to CD14+ mononuclear cells (monocytes and monocyte-derived macrophages) in an efficient and specific manner. The embodiment of the invention makes use of the chimeric human adenovirus vectors 5 carrying the short fiber of enterotropic Ad40 to transfer genetic material to the target CD14+ mononuclear cells.Type: ApplicationFiled: April 28, 2010Publication date: February 23, 2012Applicants: UNIVERSITAT AUTÒNOMA DE BARCELONA, FUNDACIÓ PRIVADA INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANCATS, FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL, GRIFOLS, S.A.Inventors: Miquel Àngel Gassull Duro, Adolfo Rio Fernandez, Ester Fernandez Gimeno, Miguel Chillón Rodriguez
-
Publication number: 20120027803Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.Type: ApplicationFiled: June 3, 2011Publication date: February 2, 2012Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah MANOHARAN, Martin Maier, Muthusamy Jayaraman, Shigeo Matsuda, Narayanannair K. Jayaprakash, Kallanthottathil G. Rajeev, Akin Akinc, Thomas A. Baillie
-
Publication number: 20120021043Abstract: The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.Type: ApplicationFiled: January 28, 2009Publication date: January 26, 2012Applicant: CureVac GmbHÛInventors: Thomas Kramps, Sohnke Voss, Jochen Probst, Ingmar Hoerr
-
Publication number: 20120014976Abstract: The disclosure provides adjuvants, immunogenic compositions, and methods useful for vaccination and immune response. In particular, the disclosure provides a class of adjuvants comprising cationic lipid:co-lipid mixtures and methods for delivering formulated compositions.Type: ApplicationFiled: September 23, 2011Publication date: January 19, 2012Applicant: Vical IncorporatedInventors: Jukka Hartikka, Sean M. Sullivan, Joel D. Enas, Alain Rolland
-
Patent number: 8097239Abstract: The present invention relates to formulations of a lipid based controlled-release matrix, a polyhydroxy component and a bioactive agent. Such formulation are useful in the delivery of the bioactive compounds. The invention also relates to the use of a polyhydroxy component for increasing the solubility of a bioactive compound, especially a peptide in a lipid-based controlled-release matrix.Type: GrantFiled: October 24, 2007Date of Patent: January 17, 2012Assignee: Camurus ABInventors: Markus Johnsson, Fredrik Tiberg, Catalin Nistor
-
Publication number: 20120009222Abstract: The present invention provides lipidoids that can be used to modulate the immune response in a subject. Lipidoids are prepared by the conjugate addition of an amine to an acrylate to acrylamide. The lipidoids form complexes or particles with an immunostimulatory polynucleotide, which are then administerd to a subject. Such compositions have been found to stimulate the production of cytokines and increase both humoral and cell-mediate immune response. The invention also provides pharmaceuti-cal compositions thereof and methods for using the same.Type: ApplicationFiled: October 27, 2009Publication date: January 12, 2012Applicant: Massachusetts Institute of TechnologyInventors: David-Huy Nhu Nguyen, Daniel Griffith Anderson, Robert S. Langer, Kerry Peter Mahon
-
Patent number: 8092813Abstract: When using squalene in a vaccine adjuvant, there is a possibility of contamination with polychlorinated biphenyls (PCBs). Environmental exposure to PCBs may adversely affect children's immune responses to routine vaccinations. Thus the invention uses squalene with low or no PCB contamination, particularly when derived from shark liver.Type: GrantFiled: October 14, 2008Date of Patent: January 10, 2012Assignee: Novartis AGInventor: Deborah L. Novicki
-
Publication number: 20120003277Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the invention find use in, among other things, clinical (e.g., therapeutic and preventative medicine (e.g., vaccination)) and research applications.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: NANOBIO CORPORATION, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: James R. Baker, JR., Tarek Hamouda, Susan M. Ciotti
-
Publication number: 20110311562Abstract: It was observed that a highly purified preparation of polar glycolipids extracted from cells of the cyanobacterium Oscillatoria Planktothrix is characterized by the presence of at least one species of high molecular weight glycolipid comprising one or more units of rhamnose. In such mixture, having a level of nucleic acid contamination lower than (or equal to) 3%, an inhibitory activity toward ATP synthase (ATP-SX) was identified which is capable of decreasing the level of extracellular ATP and thereby the extent of the inflammatory response.Type: ApplicationFiled: February 17, 2010Publication date: December 22, 2011Inventor: Monica Molteni
-
Publication number: 20110311583Abstract: (A1) Translate this text The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.Type: ApplicationFiled: November 10, 2009Publication date: December 22, 2011Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah Manoharan, kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Narayanannair, Martin Maier, Laxman Eltepu
-
Publication number: 20110287087Abstract: The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of anti-bodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CD8 response which has been reported to improve the effect of vaccines against e.Type: ApplicationFiled: November 10, 2009Publication date: November 24, 2011Applicant: Statens Serum InstitutInventors: Dennis Christensen, Karen Smith Korsholm, Else Marie Agger, Peter Andersen
-
Patent number: 8063020Abstract: A method for treating conditions related to lack of blood supply with a lipid based resuscitation fluid is disclosed. The resuscitation fluid contains a lipid component and an aqueous carrier. The lipid component forms an emulsion with the aqueous carrier. The resuscitation fluid can be used to increase the blood pressure and to carry oxygen to tissues. The resuscitation fluid can also be used for preserving the biological integrity of donor organs for transplantation.Type: GrantFiled: December 16, 2008Date of Patent: November 22, 2011Inventor: Cuthbert O. Simpkins
-
Publication number: 20110280893Abstract: The invention provides functionalized monosaccharides and disaccharides suitable for use in synthesizing a lipid A derivative, as well as methods for synthesizing and using a synthetic lipid A derivative.Type: ApplicationFiled: September 5, 2008Publication date: November 17, 2011Applicant: UNIVERSITY OF GEORGIA RESEACH FOUNDATION, INCInventor: Geert-Jan Boons
-
Publication number: 20110262488Abstract: The present application relates to a novel HIV-1 envelope glycoprotein which may be utilized as an HIV-1 vaccine immunogen, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.Type: ApplicationFiled: March 2, 2011Publication date: October 27, 2011Inventors: Sanjay K. Phogat, Wayne C. Koff, Charles Richter King, Denise Wagner, Simon Hoffenberg
-
Publication number: 20110256175Abstract: The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: October 9, 2009Publication date: October 20, 2011Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, TEKMIRA PHARMACEUTICALS CORPORATIONInventors: Michael J. Hope, Sean C. Semple, Jianxin Chen, Thomas D. Madden, Pieter R. Cullis, Marco A. Ciufolini, Barbara Low Shoud Mui
-
Publication number: 20110243969Abstract: A method for preparing purified yeast is disclosed, where the squalene source is a yeast that hyper-produces squalene. The squalene is useful for pharmaceutical purposes. For instance, it can be used to prepare an oil-in-water emulsion, and the emulsion is particularly suitable for use as an immunological adjuvant.Type: ApplicationFiled: August 28, 2009Publication date: October 6, 2011Inventor: Michael Broeker
-
Publication number: 20110162982Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants.Type: ApplicationFiled: December 3, 2010Publication date: July 7, 2011Applicant: Novartis Vaccines and Diagnostic, GmbH & Co. KGInventors: Gottfried Kraus, Robert Eskes
-
Publication number: 20110165193Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane.Type: ApplicationFiled: December 3, 2010Publication date: July 7, 2011Applicant: Novartis Vaccines and Diagnostics, GmbH & Co. KGInventors: Harald Rueckl, Hanno Scheffczik
-
Publication number: 20110142914Abstract: The present disclosure provides methods and compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent. In embodiments the compositions may be introduced by inhalation.Type: ApplicationFiled: December 5, 2008Publication date: June 16, 2011Applicant: CYTOTECH LABS, LLCInventors: Indushekhar Persaud, John Patrick McCook, Niven Rajin Narain
-
Patent number: 7943588Abstract: The present invention is a method for preventing or treating neuropathic pain. Using an agent to decrease the expression or activity of Toll-like receptor 4 (TLR4), behavioral hypersensitivity is attenuated thereby preventing or treating neuropathic pain in a subject in need of such treatment.Type: GrantFiled: March 27, 2007Date of Patent: May 17, 2011Assignee: Trustees of Dartmouth CollegeInventors: Joyce A. DeLeo, Flobert Y. Tanga
-
Patent number: 7943154Abstract: A process is described for the preparation of storage-stable, multiple emulsions of the water/oil/water (W/O/W) type which comprise one or more active ingredients. The process comprises the steps a) stirring the active ingredient into an aqueous phase, b) emulsifying the aqueous phase by passing the aqueous phase through a large-pored, porous membrane into an oil phase, c) phase inversion of the emulsion from b), by cooling the mixture at a cooling rate of at least 0.3 K/min, where an emulsifier is added either to the aqueous phase in a) or to the oil phase in b) or to both phases.Type: GrantFiled: October 29, 2004Date of Patent: May 17, 2011Assignee: Bayer Technology Services GmnHInventors: Olaf Stange, Martina Mutter, Tanja Oswald, Mark Schmitz
-
Publication number: 20110111016Abstract: The present invention provides compositions comprising synthetic non-DNA base-containing polynucleotide sequences of 3 to 30 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases, in combination with a pharmaceutically acceptable vehicle, particularly one or more adjuvant vehicle, and one or more antigen. The present invention relates to methods of administering these compositions for inducing or modulating an immune response in vitro or in vivo, and particularly for activating antigen presenting cells.Type: ApplicationFiled: October 8, 2010Publication date: May 12, 2011Inventors: Nigel C. Phillips, Mario C. Filion
-
Publication number: 20110110972Abstract: Compositions and methods for treating immune cells and activating immune responses are disclosed. The compositions comprise one or more optically active chiral cationic lipids.Type: ApplicationFiled: April 14, 2009Publication date: May 12, 2011Applicant: PDS BIOTECHNOLOGY CORPORATIONInventors: Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya Toney Johnson, Gregory Conn, Frank Bedu-addo, Leaf Huang
-
Patent number: 7906122Abstract: The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for stimulating or enhancing an immune response of a subject to protect against Hepatitis B Virus (HBV) infection. Other aspects of the invention concern methods for stimulating or enhancing an immune response of a subject to protect against Hepatitis B Virus (HBV) infection, by the use of the sphingoid-polyalkylamine conjugate, complexes comprising the sphingoid-polyalkylamine conjugate and a biologically active molecule, the latter, having an effect of stimulating or enhancing an immune response of a subject against to protect Hepatitis B Virus (HBV) infection, as well as kits making use of said conjugates and complexes. A preferred conjugate according to the invention is N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine (CCS).Type: GrantFiled: February 2, 2006Date of Patent: March 15, 2011Assignees: Yissum Research Development Company of the Hebrew University of Jersusalem, Biolab Ltd., Nasvax Ltd.Inventors: Yechezkel Bareholz, Eliezer Kedar, Sarit Samira
-
Publication number: 20110033485Abstract: The invention provides analogs of alpha-galactosyl ceramide that increase the immune response elicited by various antigens. It also provides methods of using such compounds to increase the effectiveness of vaccines.Type: ApplicationFiled: October 10, 2008Publication date: February 10, 2011Inventor: Luigi Panza
-
Publication number: 20110033484Abstract: An adjuvant combination that stimulates immune activation or response includes a hydrophobic immune adjuvant and a pathogen derived lipoprotein that chaperones the hydrophobic immune adjuvant to an immune receptor.Type: ApplicationFiled: January 26, 2010Publication date: February 10, 2011Inventors: Clifford V. Harding, W. Henry Boom, Michael G. Drage, Nicole D. Pecora
-
Patent number: 7871631Abstract: The present invention provides an antihuman TNF-? antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-? antibody; and a kit preparation wherein a freeze-dried antihuman TNF-? antibody and the activity lowering inhibitor in the above repeated administration of the anti-TNF-? antibody are separately contained in a plastic container so that they can communicate with each other. According to the present invention, in the drug therapy to the patients with inflammatory bowel syndrome, therapeutic agents which inhibit the inflammation for long periods without accompanying serious side effects can be provided.Type: GrantFiled: September 18, 2009Date of Patent: January 18, 2011Assignee: Ajinomoto Co., Inc.Inventor: Takayuki Matsumoto
-
Publication number: 20110002983Abstract: The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein R1 R4 R5 R6 and R7 are each independently selected from hydrogen, acetyl, hydrocarbyl, a lipid moiety and a lipid acyl moiety; R2 is a hydroxyl, a hydrocarbyl, a lipid moiety, a lipid acyl moiety; or an amino hydrocarbyl group optionally substituted with a hydrocarbyl, a lipid moiety or a lipid acyl moiety; R3 and R8 are each independently selected from acetyl, a hydrocarbyl, a lipid moiety and a lipid acyl moiety; X is a peptide chain; The above normuramylglycopeptide compounds can be located in liposomes and micelles and can function as immunomodulators, along with a desired antigen (or DNA encloding the antigen), in (e.g. DNA) vaccines.Type: ApplicationFiled: March 17, 2009Publication date: January 6, 2011Inventors: Karsten Hipler, Andrew Miller, Jaroslav Turanek, Miroslav Ledvina
-
Publication number: 20100316657Abstract: Archaeal lipid adjuvants are synthesized by chemically coupling various carbohydrates or anionic polar groups to the free hydroxyl(s) of archaeal lipid cores. Chemically stable lipid cores such as saturated archaeol and caldarchaeol are obtained from appropriate Archaea. Archaeosome lipid vesicles are formulated from the synthetic lipids selected to serve as antigen carriers that target antigen-presenting cells and promote an appropriate immune response to the antigen.Type: ApplicationFiled: March 30, 2007Publication date: December 16, 2010Inventors: Dennis Sprott, Dennis M. Whitfield, Lakshmi Krishnan
-
Patent number: 7850973Abstract: The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of A? in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of A?, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to A?. In another aspect, the immunogenic fragment of A? is capable of elevating plasma A? levels. The immunogenic fragments comprise linear or multivalent peptides of A?. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.Type: GrantFiled: May 1, 2006Date of Patent: December 14, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Victor M. Garsky, Joseph G. Joyce, Paul M. Keller, Gene Kinney, Xiaoping Liang, John W. Shiver
-
Patent number: 7838019Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.Type: GrantFiled: March 24, 2004Date of Patent: November 23, 2010Assignee: Isconova ABInventors: Bror Morein, Karin Lovgren Bengtsson
-
Publication number: 20100278875Abstract: The present invention provides PGE2 as a novel adjuvant for enhancing the immune response in a host, as well as methods of using PGE2 to enhance B cell response and thereby increasing antibody titer against a given immunogen are also disclosed and antibodies produced by at least one method of the present invention.Type: ApplicationFiled: September 28, 2007Publication date: November 4, 2010Inventors: Jill Giles-Komar, Michael A. Rycyzyn
-
Patent number: 7824686Abstract: The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in eliciting the production of antibodies that recognize epitopes of native proteins.Type: GrantFiled: November 20, 2008Date of Patent: November 2, 2010Assignee: Immunovaccine Technologies, Inc.Inventors: Robert George Brown, Bill Pohajdak, Warwick Charles Kimmins
-
Patent number: 7815920Abstract: An antigen-containing formulation is provided, comprising: (a) an antigen; (b) a TH1-inducing adjuvant; and (c) a sparingly soluble amino acid or a derivative thereof. The adjuvant may be, for example, monophosphoryl lipid A, 3?-de-O-acetylated monophosphoryl lipid A, derivatives thereof, or any other adjuvant that enhances an individual's TH1 response to the antigen. Suitable amino acids include tyrosine, tryptophan, derivatives thereof, and the like. Methods for using the formulation are also provided; in a particularly preferred embodiment, the formulation is used as a vaccine.Type: GrantFiled: August 2, 2002Date of Patent: October 19, 2010Assignee: Allergy Therapeutics (UK) LtdInventors: Alan Wheeler, Anthony Berry
-
Publication number: 20100247537Abstract: Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (?-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.Type: ApplicationFiled: April 25, 2008Publication date: September 30, 2010Inventors: Cory Ahonen, Randolph Noelle
-
Publication number: 20100233207Abstract: The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI-type immune response characterized by enhanced IL-12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.Type: ApplicationFiled: May 22, 2007Publication date: September 16, 2010Applicants: New York University, Research Foundation of the City University of New York, The Aaron Diamond AIDS Research Center for the City of New York, Inc.Inventors: Moriya Tsuji, Guangwu Chen, Richard W. Franck, Guangli Yang
-
Publication number: 20100221269Abstract: The invention provides functionalized monosaccharides and disaccharides suitable for use in synthesizing a lipid A derivative, as well as methods for synthesizing and using a synthetic lipid A derivative.Type: ApplicationFiled: September 5, 2008Publication date: September 2, 2010Applicant: UNIVERSITY OF GEORGIA RESEACH FOUNDATION, INCInventor: Geert-Jan Boons
-
Patent number: 7776324Abstract: The present invention relates to a method for producing a composition for use as a vaccine for treatment or prevention of cancer. The method includes the steps of isolating dendritic cells from a blood, bone marrow or other tissue sample of a patient suffering from cancer or from an unrelated donor, culturing the dendritic cells under conditions and pulsing the dendritic cells with tumour cell lysate or an antigen released by the type of tumour cell and a tocotrienol.Type: GrantFiled: February 3, 2007Date of Patent: August 17, 2010Assignee: Malaysian Palm Oil Board (MPOB)Inventors: Kalanithi Nesaretnam, Sitti Rahma Abdul Hafid, Kanga Rani Selvaduray, Tan Sri Datuk Dr. Yusof Basiron
-
Publication number: 20100172941Abstract: This disclosure provides adjuvant compositions that are capable of modulating the immune response in a subject. These adjuvant compositions may also be used enhance the immunogenicity of antigens. Also provided are methods of making the adjuvant compositions as well as methods of using the adjuvant compositions.Type: ApplicationFiled: January 4, 2010Publication date: July 8, 2010Inventors: Michael Vajdy, Shore Padrah
-
Patent number: 7749520Abstract: The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.Type: GrantFiled: July 5, 2005Date of Patent: July 6, 2010Assignee: Statens Serum InstitutInventors: Jesper Davidsen, Peter Andersen, Ida Rosenkrands
-
Patent number: 7727973Abstract: Compounds of the formula: and compositions containing one or more such compounds, the compositions preferably being suitable for topical application to the skin.Type: GrantFiled: October 26, 2004Date of Patent: June 1, 2010Assignee: L'OrealInventor: Richard Martin
-
Patent number: 7713942Abstract: The present invention pertains to complexes comprising sterols and saponins. The complexes are capable of binding a genetic determinant including a polynucleotide. The complexes may further comprise a lipophilic moiety, optionally a lipophilic moiety comprising a contacting group and/or a targeting ligand, and/or a saccharide moiety. The complexes may further comprise an immunogenic determinant and/or an antigenic determinant and/or a medicament and/or a diagnostic compound. The complexes may in even further embodiments be encapsulated by an encapsulation agent including a biodegradable microsphere. The present invention also pertains to pharmaceutical compositions and methods of treatment of an individual by therapy and/or surgery, methods of cosmetic treatment, and diagnostic methods practised on the human or animal body.Type: GrantFiled: April 4, 2002Date of Patent: May 11, 2010Assignee: Nordic Vaccine Technology A/SInventors: Kristian Dalsgaard, Nikolai Søren Kirkby
-
Patent number: 7666447Abstract: Methods and compositions for the prevention, therapy and/or treatment of several disease states. The methods comprise the administration of a therapeutically effective amount of a composition including krill extract and conjugated linoleic acid. In addition, the present invention provides new and improved therapeutic compositions including krill extracts and conjugated linoleic acid.Type: GrantFiled: October 8, 2004Date of Patent: February 23, 2010Assignee: PharmanutrientsInventor: Susie Rockway
-
Publication number: 20100015215Abstract: The present invention relates to adjuvants of the glycolipid type and their uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new uses of compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours and allergies. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants.Type: ApplicationFiled: September 6, 2007Publication date: January 21, 2010Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman, Götz Milkereit